Case Report: Dacomitinib is effective in lung adenocarcinoma with rare EGFR mutation L747P and brain metastases

Yibin Li; Weixi Guo; Bin Jiang; Chengkun Han; Feng Ye; Jingxun Wu

doi:10.3389/fonc.2022.863771

Frontiers in Oncology (Aug 2022)

Case Report: Dacomitinib is effective in lung adenocarcinoma with rare EGFR mutation L747P and brain metastases

Yibin Li,
Weixi Guo,
Bin Jiang,
Chengkun Han,
Feng Ye,
Jingxun Wu

Affiliations

Yibin Li: Department of Medical Oncology, The First Affiliated Hospital of Xiamen University, Xiamen, China
Weixi Guo: Department of Thoracic Surgery, The First Affiliated Hospital of Xiamen University, Xiamen, China
Bin Jiang: Department of Neurology, The First Affiliated Hospital of Xiamen University, Xiamen, China
Chengkun Han: Department of Radiology, The First Affiliated Hospital of Xiamen University, Xiamen, China
Feng Ye: Department of Medical Oncology, The First Affiliated Hospital of Xiamen University, Xiamen, China
Jingxun Wu: Department of Medical Oncology, The First Affiliated Hospital of Xiamen University, Xiamen, China

DOI: https://doi.org/10.3389/fonc.2022.863771
Journal volume & issue: Vol. 12

Abstract

Read online

Due to the low incidence of rare EGFR mutation, its response to EGFR-TKI has not been fully investigated. L747P is a rare EGFR mutation in EGFR exon 19. Previous case reports showed that patients with EGFR L747P mutation responded to afatinib treatment. However, we encountered a patient with EGFR L747P who was resistant to afatinib but responded to dacomitinib. It is the first case report of the effective application of dacomitinib in a patient with L747P mutation and BMS, and the efficacy of BMS achieved PR.

Published in Frontiers in Oncology

ISSN: 2234-943X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.frontiersin.org/journals/oncology/

About the journal

Abstract

Keywords